A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (CAL-101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic Leukemia

Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (CAL-101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic Leukemia

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Idelalisib (Primary) ; Rituximab
  • Indications Chronic lymphocytic leukaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 06 Dec 2016 Results assessing outcomes presented of patients with Complex Karyotype (n=127) at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 06 Dec 2016 Results of quantitative analysis of various immune cell subsets from this and other four studies (n = 1480)) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 06 Dec 2016 Results (n=13) of this and two other studies assessing mutational mechanism of Idelaliisb presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top